The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Dulac Edward J Iii since 2021.
This trader's CIK number is 1821530.
At the time of last reporting, Dulac Edward J Iii was the EVP, Chief Financial Officer of Intellia Therapeutics, Inc.. (stock ticker symbol NTLA).
Also see all insider trading activities at Intellia Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | FATE | 0 | $0 | 14,059 | $58,923 | 0 | $0 |
| 2023 | FATE | 0 | $0 | 11,485 | $43,786 | 0 | $0 |
| 2022 | FATE | 0 | $0 | 6,905 | $240,667 | 0 | $0 |
| 2021 | FATE | 0 | $0 | 38,911 | $2,484,117 | 31,762 | $1,128,186 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NTLA | 0 | $0 | 7,462 | $104,617 | 0 | $0 |
1. Fate Therapeutics Inc (FATE)
2. Intellia Therapeutics, Inc. (NTLA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-01-29 | FATE | Sale | 1,849 | 5.00 | 9,245 |
| 2024-01-09 | FATE | Sale | 7,028 | 4.37 | 30,712 |
| 2024-01-02 | FATE | Sale | 5,182 | 3.66 | 18,966 |
| 2023-12-18 | FATE | Sale | 1,585 | 3.50 | 5,547 |
| 2023-08-18 | FATE | Sale | 4,718 | 2.80 | 13,210 |
| 2023-07-05 | FATE | Sale | 5,182 | 4.83 | 25,029 |
| 2022-08-18 | FATE | Sale | 5,135 | 30.08 | 154,460 |
| 2022-01-11 | FATE | Sale | 1,770 | 48.70 | 86,207 |
| 2021-12-20 | FATE | Option Ex | 14,437 | 35.52 | 512,802 |
| 2021-12-20 | FATE | Sale | 15,977 | 60.00 | 958,620 |
| 2021-09-28 | FATE | Sale | 19,460 | 62.53 | 1,216,833 |
| 2021-09-28 | FATE | Option Ex | 17,325 | 35.52 | 615,384 |
| 2021-08-19 | FATE | Sale | 3,474 | 88.85 | 308,664 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-23 | NTLA | Sale | 7,462 | 14.02 | 104,617 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Dulac Edward J Iii (EVP, Chief Financial Officer of Intellia Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.